Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22

Rhea-AI Filing Summary

Cabaletta Bio director Catherine Bollard received a stock option grant covering 22,000 shares of common stock. The option has an exercise price of $3.22 per share and gives her the right to buy 22,000 shares in the future. It vests in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting, providing equity-based compensation rather than an open-market share purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bollard Catherine

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 22,000 options Exercise price: $3.22 per share Underlying shares: 22,000 shares +2 more

5 metrics

Option grant size 22,000 options Stock Option (Right to Buy) covering common stock

Exercise price $3.22 per share Conversion or exercise price of the option

Underlying shares 22,000 shares Underlying Cabaletta Bio common stock

Expiration date June 8, 2036 Option expiration date

Shares following transaction 22,000 options Total derivative securities after this grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "3.2200" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-08T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

vest in full financial

"This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bollard Catherine

(Last) (First) (Middle)

C/O CABALETTA BIO, INC.

2929 ARCH STREET, SUITE 600

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cabaletta Bio, Inc. [ CABA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.22	06/09/2026		A		22,000		(1)	06/08/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders.

	/s/ Michael Gerard, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cabaletta Bio (CABA) report for Catherine Bollard?

Cabaletta Bio reported that director Catherine Bollard received a stock option grant for 22,000 shares. The options are a compensation award, not an open-market purchase, and give her the right to buy common stock at a fixed exercise price in the future.

How many Cabaletta Bio (CABA) options did Catherine Bollard receive and at what price?

Catherine Bollard was granted stock options covering 22,000 shares of Cabaletta Bio common stock. The options carry an exercise price of $3.22 per share, setting the cost she must pay per share if she later chooses to exercise them.

When do Catherine Bollard’s Cabaletta Bio (CABA) stock options vest?

Catherine Bollard’s options vest in full on the earlier of June 9, 2027, or the date of Cabaletta Bio’s next annual stockholder meeting. She must wait until this vesting event before the entire 22,000-share option becomes exercisable.

Did Catherine Bollard buy or sell Cabaletta Bio (CABA) shares in this Form 4?

The Form 4 shows an acquisition of derivative securities through a stock option grant, not a market trade. Catherine Bollard did not buy or sell common shares on the open market; she received 22,000 options as a grant at a $3.22 exercise price.

What is the expiration date of Catherine Bollard’s Cabaletta Bio (CABA) stock options?

The stock options granted to Catherine Bollard expire on June 8, 2036. If she does not exercise the 22,000 options by that expiration date at the $3.22 exercise price, the right to purchase the underlying shares will lapse.

How many Cabaletta Bio (CABA) options does Catherine Bollard hold after this grant?

Following this grant, Catherine Bollard’s reported holdings include 22,000 stock options. These options relate to 22,000 underlying Cabaletta Bio common shares and represent her position from this filing, subject to vesting and the stated expiration date in 2036.